Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00500812 · ClinicalTrials.gov registry record · Phase 1

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

A Phase 1 study of Spinal Cord Injury, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
8
Study locations

NCT00500812 is a Phase 1 study of Spinal Cord Injury that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 48 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (44% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00500812, a Phase 1 study of Spinal Cord Injury, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
8
Study locations

Study Summary

This trial is a multi-center, open-label, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of Cethrin in two types of spinal cord injury patients: those with a complete cervical injury or a complete thoracic injury. Dose levels from 0.3 mg - 9 mg of Cethrin will be administered.

Conditions Studied

Spinal Cord Injury

Interventions

  • DRUG Cethrin

Study Locations (8)

Ontario

  • Sunnybrooke Health Sciences Centre - Toronto
  • Toronto Western Hospital - Toronto

Arizona

  • St. Joseph's Hospital & Medical Center - Phoenix

Ohio

  • University of Cincinnati Mayfield Clinic and Spine Institute - Cincinnati

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Virginia

  • Univ.of Virginia Health System - Charlottesville

Washington

  • University of Washington Harborview Medical Center - Seattle

Quebec

  • Hopital du Sacre-Coeur de Montreal - Montreal

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2005-02
Est. Completion 2009-02
Phase Phase 1

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00500812

The ClinicalTrials.gov registry entry for NCT00500812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (44% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which Cethrin is the first listed.

NCT00500812 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Ontario, Arizona, Ohio.

Frequently Asked Questions

What is clinical trial NCT00500812 about?

NCT00500812 is a clinical study titled "A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries". This trial is a multi-center, open-label, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of Cethrin in two types of spinal cord injury patients: those with a complete cervical injury or a complete thoracic injury. Dose levels from 0.3 mg - 9 mg of Cethrin wi...

What is the current status of trial NCT00500812?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-02. Estimated completion is 2009-02.

What conditions does trial NCT00500812 study?

This clinical trial studies the following conditions: Spinal Cord Injury.

What interventions are being tested in trial NCT00500812?

The interventions under investigation include: Cethrin (DRUG).

Who is sponsoring clinical trial NCT00500812?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00500812 being conducted?

This trial has 8 study locations across Arizona, Ohio, Pennsylvania, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinal Cord Injury

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.